

PRESS RELEASE

SPL Medical has entered into an Agreement with Sanochemia Pharmazeutika GmbH for supply and worldwide distribution of Ferrotran® (Ferumoxtran) for detection of Lymph node metastases by Magnetic Resonance Imaging (MRI).



Nijmegen, The Netherlands, 11.03.2024 – The business agreement, signed by SPL Medical and Sanochemia Pharmazeutika, is a comprehensive contract. The agreement grants Sanochemia worldwide exclusivity regarding the supply and distribution of *Ferrotran*® (an iron oxide-based nanoparticle) for use in Magnetic Resonance Imaging (MRI) except for Germany, Austria and Switzerland. These 3 countries are already contracted to b.e.imaging GmbH, Germany.

The agreement includes downpayments and purchase commitments for future commercial sales and future options.

With *Ferrotran*®, Sanochemia is getting access to a highly attractive platform technology based on iron oxide nanoparticles, which open the door for functional diagnostics in MRI.

"By detecting even the smallest lymph node metastases in prostate cancer patients, the product is opening impressive diagnostic perspectives and treatment for patients worldwide", says Thomas Erkinger, Managing Director of Sanochemia. "At Sanochemia we are aiming to save patients' lives by contributing to the future of radiology. Thus, Ferrotran® is an extremely exciting product to add to our portfolio of Gadolinium-free contrast agents."

"By this agreement with Sanochemia, SPL medical is gaining access to the worldwide market of medical imaging via the extensive marketing network of Sanochemia thus making Ferrotran® available for the benefit of a broad patient population in a critical oncological status throughout the worlds", says Dr. Jürgen Feuerstein CEO for SPL Medical.

About Ferrotran®:

Ferrotran® belongs to the group of USPIO's (Ultrasmall Superparamagnetic Particles of Iron Oxide). Ferrotran® can be applied in MRI as a safe bloodpool agent for angiography and for functional diagnostics in detection of even the smallest lymph node metastases in prostate cancer patients and is currently under investigation for use in various other cancers.

Ferrotran® is safe, as it is based on iron and therefore metabolized naturally in the body.

Ferrotran® is in advanced phase III in various prestigious European University Hospitals. Ferrotran® has been applied successfully in over 700 patients in the Netherlands and Switzerland in special approval permissions.

**About SPL Medical:**

SPL medical is a spin-off of the Radboud university medical center and is funded additionally by Oost NL, a Dutch regional venture capital company, and b.e.imaging GmbH, a German company specialized in the development and commercialization of contrast agents.

About Sanochemia Pharmazeutika:

Sanochemia is a leading supplier of pharmaceuticals for radiological applications in the center of Europe. In addition to classic contrast agents, the company focuses on organ-specific and gadolinium-free specialty products. The company's imaging agents are used by doctors and hospitals in over 50 countries worldwide for diagnostic imaging in MR and CT procedures. At the Austrian production site, more than 200 employees ensure that drug products (FDF) and active pharmaceutical ingredients (APIs) are manufactured to the highest pharmaceutical quality standards.
www.sanochemia.com

For more information about Ferrotran®, the clinical trials or SPL Medical:

Dr. Juergen Feuerstein (CEO) at +49 171 173 5476